gemtuzumab ozogamicin

Latest news

Tag

Navigating Therapeutic Approaches in Pediatric Relapsed Acute Myeloid Leukemia: Current Trends and Comparative Outcomes

This article reviews the variability and comparative effectiveness of re-induction treatments in pediatric relapsed AML, highlighting the role of gemtuzumab ozogamicin and chemotherapy backbones in improving remission rates but not overall

Sep 3, 2026

Hematology-Oncology

DAGO2 (daunorubicin+cytarabine+fractionated gemtuzumab) outperforms CPX‑351 in older adults with non‑adverse‑risk AML: insights from NCRI AML18

In NCRI AML18 (n=439, median age 68), DAGO2 produced higher early CR/MRD‑negative rates and superior 3‑year EFS and OS versus CPX‑351 in older adults without adverse‑risk cytogenetics; survival differences persisted across key subgroups inc

Nov 15, 2025Sign in to read

Clinical Updates

Sustained Remission in Acute Promyelocytic Leukemia with ATO-ATRA and Gemtuzumab Ozogamicin: Long-Term Phase 2 Outcomes

A phase 2 study shows that combining all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin yields a 94% cure rate in acute promyelocytic leukemia with favorable safety over five years.

Sep 10, 2025